Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome.
Piccolo, Raffaele; Di Gioia, Giuseppe; Niglio, Tullio; D'Anna, Carolina; De Rosa, Roberta; Strisciuglio, Teresa; Bevilacqua, Michele; Piscione, Federico; Cirillo, Plinio; Galasso, Gennaro.
; 65(2): 130-6, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23221279
Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects.
The future of P2Y12 receptor antagonists.
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease.
Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.
Role of phenotypic and genetic testing in managing clopidogrel therapy.
P2Y12 platelet inhibition in clinical practice.
Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study.
Neue Antiaggregantien - klinische Aspekte.
[Experience with Prasugrel in the Treatment of Patients with Acute Coronary Syndrome].
Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.